- Home
- PTN vs ITRM Comparison
PTN vs ITRM Comparison
Compare PTN & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTN
- ITRM
- Stock Information
- Founded
- PTN 1986
- ITRM 2015
- Country
- PTN United States
- ITRM Ireland
- Employees
- PTN N/A
- ITRM N/A
- Industry
- PTN Biotechnology: Pharmaceutical Preparations
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- PTN Health Care
- ITRM Health Care
- Exchange
- PTN Nasdaq
- ITRM Nasdaq
- Market Cap
- PTN 25.4M
- ITRM 24.7M
- IPO Year
- PTN 1993
- ITRM 2018
- Fundamental
- Price
- PTN $0.96
- ITRM $1.37
- Analyst Decision
- PTN Strong Buy
- ITRM Strong Buy
- Analyst Count
- PTN 1
- ITRM 1
- Target Price
- PTN $17.00
- ITRM $5.00
- AVG Volume (30 Days)
- PTN 258.0K
- ITRM 7.1M
- Earning Date
- PTN 11-14-2024
- ITRM 11-14-2024
- Dividend Yield
- PTN N/A
- ITRM N/A
- EPS Growth
- PTN N/A
- ITRM N/A
- EPS
- PTN N/A
- ITRM N/A
- Revenue
- PTN $2,384,113.00
- ITRM N/A
- Revenue This Year
- PTN N/A
- ITRM N/A
- Revenue Next Year
- PTN N/A
- ITRM N/A
- P/E Ratio
- PTN N/A
- ITRM N/A
- Revenue Growth
- PTN N/A
- ITRM N/A
- 52 Week Low
- PTN $0.68
- ITRM $0.81
- 52 Week High
- PTN $5.65
- ITRM $2.50
- Technical
- Relative Strength Index (RSI)
- PTN 43.15
- ITRM 54.25
- Support Level
- PTN $1.06
- ITRM $1.25
- Resistance Level
- PTN $1.26
- ITRM $1.61
- Average True Range (ATR)
- PTN 0.14
- ITRM 0.14
- MACD
- PTN -0.01
- ITRM 0.00
- Stochastic Oscillator
- PTN 1.35
- ITRM 46.67
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.